Ladenburg raised the firm’s price target on Vericel (VCEL) to $56 from $54 and keeps a Buy rating on the shares. The company delivered strong Q3 results, marked by record revenue, substantial margin expansion, and key regulatory advancements, the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter